0001209191-20-011785.txt : 20200221
0001209191-20-011785.hdr.sgml : 20200221
20200221191626
ACCESSION NUMBER: 0001209191-20-011785
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200220
FILED AS OF DATE: 20200221
DATE AS OF CHANGE: 20200221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Osborne Aaron
CENTRAL INDEX KEY: 0001772432
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 20641671
MAIL ADDRESS:
STREET 1: C/O ADVERUM BIOTECHNOLOGIES, INC.
STREET 2: 1035 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1035 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-272-6269
MAIL ADDRESS:
STREET 1: 1035 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc.
DATE OF NAME CHANGE: 20100921
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-20
0
0001501756
Adverum Biotechnologies, Inc.
ADVM
0001772432
Osborne Aaron
C/O ADVERUM BIOTECHNOLOGIES, INC.
1035 O'BRIEN DRIVE
MENLO PARK
CA
94025
0
1
0
0
Chief Medical Officer
Stock Option (Right to Buy)
15.75
2020-02-20
4
A
0
150000
0.00
A
2030-02-19
Common Stock
150000
150000
D
Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 20, 2020 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Aaron Osborne, by /s/ Thomas Leung, Attorney-in-Fact
2020-02-21